Breaking Finance News

A statement released earlier today by Raymond James about Regenxbio (NDAQ:RGNX) bumps the target price to $39.00

Raymond James bumped up the target of Regenxbio (NDAQ:RGNX) to $39.00 stating a potential upside of 0.16%.

On Thursday August 17, 2017, Evercore ISI released a statement on Regenxbio (NDAQ:RGNX) bumped up the target price from $0.00 to $25.00 that suggested an upside of 0.20%.

Boasting a price of $33.60, Regenxbio (NDAQ:RGNX) traded 3.56% higher on the day. With the last close up 14.57% from the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the date range. Regenxbio has recorded a 50-day average of $30.46 and a two hundred day average of $30.46. Volume of trade was down over the average, with 102,861 shares of RGNX changing hands under the typical 459,104

Performance Chart

Regenxbio (NDAQ:RGNX)

With a total market value of $0, Regenxbio has with a one year low of $15.25 and a one year high of $36.10 .

More About Regenxbio (NDAQ:RGNX)

REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.